- Home
- TVRD vs ACV Comparison
TVRD vs ACV Comparison
Compare TVRD & ACV Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- TVRD
- ACV
- Stock Information
- Founded
- TVRD 2017
- ACV 2015
- Country
- TVRD United States
- ACV United States
- Employees
- TVRD N/A
- ACV N/A
- Industry
- TVRD Biotechnology: Pharmaceutical Preparations
- ACV Finance/Investors Services
- Sector
- TVRD Health Care
- ACV Finance
- Exchange
- TVRD Nasdaq
- ACV Nasdaq
- Market Cap
- TVRD 246.5M
- ACV 234.1M
- IPO Year
- TVRD N/A
- ACV N/A
- Fundamental
- Price
- TVRD $24.14
- ACV $22.58
- Analyst Decision
- TVRD Strong Buy
- ACV
- Analyst Count
- TVRD 5
- ACV 0
- Target Price
- TVRD $59.20
- ACV N/A
- AVG Volume (30 Days)
- TVRD 38.6K
- ACV 38.8K
- Earning Date
- TVRD 08-21-2025
- ACV 01-01-0001
- Dividend Yield
- TVRD N/A
- ACV 9.20%
- EPS Growth
- TVRD N/A
- ACV N/A
- EPS
- TVRD N/A
- ACV N/A
- Revenue
- TVRD N/A
- ACV N/A
- Revenue This Year
- TVRD N/A
- ACV N/A
- Revenue Next Year
- TVRD N/A
- ACV N/A
- P/E Ratio
- TVRD N/A
- ACV N/A
- Revenue Growth
- TVRD N/A
- ACV N/A
- 52 Week Low
- TVRD $8.13
- ACV $16.82
- 52 Week High
- TVRD $34.31
- ACV $23.74
- Technical
- Relative Strength Index (RSI)
- TVRD N/A
- ACV 50.51
- Support Level
- TVRD N/A
- ACV $22.38
- Resistance Level
- TVRD N/A
- ACV $22.88
- Average True Range (ATR)
- TVRD 0.00
- ACV 0.25
- MACD
- TVRD 0.00
- ACV -0.04
- Stochastic Oscillator
- TVRD 0.00
- ACV 38.93
About TVRD Tvardi Therapeutics Inc. Common Stock
Tvardi Therapeutics Inc is a clinical-stage biopharmaceutical company focused on the development of novel, oral small molecule therapies targeting STAT3 to treat fibrosis-driven diseases. Its key product candidate, TTI-101, is in Phase 2 clinical development for the treatment of idiopathic pulmonary fibrosis (IPF), and hepatocellular carcinoma (HCC). Its second product candidate, TTI-109, is structurally related to, yet chemically distinct from, TTI-101 and is designed to enhance the ability to target STAT3.
About ACV Virtus Diversified Income & Convertible Fund of Beneficial Interest
Virtus AllianzGI Diversified Income & Convertible Fund is a diversified, limited-term, closed-end management investment company. The fund's investment objective is to provide total return through a combination of current income and capital appreciation while seeking to provide downside protection against capital loss. It invests in a diversified portfolio of convertible securities, income-producing equity securities, and income-producing debt and other instruments of varying maturities, of which a majority of the managed assets are invested in convertibles.